Luckwel Pharmaceuticals Inc.
Healthcare · Pharmaceutical Preparations · NV · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — |
| Net income | −$436,013 | −$536,432 | −$622,526 | −$537,088 | −$510,708 | −$420,728 |
| Total assets | $46,681 | $17,213 | $27,270 | $18,503 | $52,386 | $116,767 |
| Total liabilities | $490,949 | $1.3M | $819,093 | $147,800 | — | $32,822 |
| Equity | −$444,268 | −$1.3M | −$791,823 | −$129,297 | −$342,209 | $83,945 |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 147.2M | 143.4M | 143.4M | 143.4M | 18.4M | 17.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- —
- Net margin
- —
- Return on equity
- 98.1%
- Return on assets
- −934.0%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 1051.7%
- Debt / equity
- —
- Book value / share
- $-0.00
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Accruals / assets
- −509.9%clean
- Piotroski F-Score
- 3/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 2 warning● 2 good- Negative shareholder equity
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Jul 3, 2019
- NT 10-Kmissed a reporting deadline ↗Jun 29, 2018
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Entered a material agreementOct 1, 2021
- Changed auditor · Prior financials not reliable (restatement)Sep 21, 2021
- Entered a material agreement · Unregistered equity saleMay 26, 2021
- Entered a material agreement · Unregistered equity saleApr 27, 2021
- Entered a material agreementMar 22, 2021
- Unregistered equity saleFeb 12, 2021
- Entered a material agreementFeb 5, 2021
- Amended charter or bylawsJan 19, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.